Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research advancing science and patient care in cystic fibrosis, rare diseases, and related areas through multiple grant and award programs.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | 2026 (next cycle for select CF award programs)
Funding Amounts: No fixed cap; CF Research Innovation Awards: up to $750,000 over 3 years; Mentored RIA: up to $125,000 over 2 years; VIA: up to $750,000 per project.
Summary: Supports independent research, education, and advocacy initiatives in serious diseases (notably cystic fibrosis), with rolling submissions and specialized award cycles.
Key Information: Requests must align with Vertex’s disease priorities; some programs accept proposals only during RFP windows.
Description
Vertex Pharmaceuticals offers a range of funding opportunities to support independent research, educational programs, patient advocacy, and community initiatives in therapeutic areas of company focus, particularly cystic fibrosis, beta thalassemia, sickle cell disease, IgA nephropathy, pain, and other rare diseases. Funding is available through Investigator Sponsored Studies (ISS), grants for medical education and advocacy, sponsorships, and specialized award programs such as the CF Research Innovation Awards (RIA) and Vertex Innovation Awards (VIA).
Vertex’s goal is to advance scientific knowledge, improve patient care, and foster innovation in serious diseases. Funding is provided to organizations, not individuals, and is intended for independent, non-commercial activities that align with Vertex’s current areas of interest.
